Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.

Paediatric drugs - 1 May 2024

Clemente-Bautista Susana, Trocóniz Iñaki F, Segarra-Cantón Óscar, Salvador-Marín Sara, Parramón-Teixidó Carlos J, Álvarez-Beltrán Marina, López-Fernández Luís A, Colom Helena, Cabañas-Poy Maria J, Gorgas-Torner Maria Q, Miarons Marta

Abstract excerpt

BACKGROUND: Therapeutic drug monitoring (TDM) of infliximab has been shown to be a effective strategy for inflammatory bowel disease (IBD). Population pharmacokinetic (PopPK) modeling can predict trough concentrations for individualized dosing. OBJECTIVE: The aim of this study was to develop a PopPK model of infliximab in a paediatric population with IBD, assessing the effect of single nucleotide polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Agents

Share to Infant

Share to Inflammatory Bowel Diseases

Share to Infliximab

Share to Models, Biological

Source

Identifiers

PMID: 38507036
DOI: 10.1007/s40272-024-00621-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.PMID 38507036Read ↗

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.Semantic proximity Read ↗

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studySemantic proximity Read ↗

Treatment of Chronic Inflammatory Diseases – The Potential of PharmacogeneticsSemantic proximity Read ↗

Pharmacogenomics of Anti-Inflammatory Therapy: Toward Personalized Use of Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, and BiologicsSemantic proximity Read ↗

Personalized therapies in pediatric inflammatory and autoimmune diseases.Semantic proximity Read ↗

Personalizing therapy selection in inflammatory bowel disease.Semantic proximity Read ↗

Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma.Semantic proximity Read ↗

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.Semantic proximity Read ↗

Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach.Semantic proximity Read ↗

Association of FKBP4 gene polymorphisms with glucocorticoid efficacy in pediatric systemic lupus erythematosus.Semantic proximity Read ↗

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.Semantic proximity Read ↗

Global Estimates and Determinants of Antituberculosis Drug Pharmacokinetics in Children and Adolescents: A Systematic Review and Individual Patient Data Meta-AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.